NEW YORK, March 14 - Ciphergen Biosystems of Fremont, Calif., said Wednesday it opened a new center in Malvern, Pa., to conduct proteomic research for the company’s customers.
The Biomarker Discovery Center’s first project will entail a clinical stratification pilot study for an unnamed pharmaceutical company. The center will also support the company’s cancer biomarker project with Johns Hopkins School of Medicine.
"The opening of this center is the next step in our providing advanced proteomics services to our pharmaceutical and biotechnology clients," William Rich, CEO of Ciphergen, said in a statement.
"In particular, we see a major opportunity in using our ProteinChip System to perform differential protein expression analysis to discover biomarkers that may have major applications in pre-clinical and clinical drug development," Rich said.
The ProteinChip System is designed to be used for protein discovery, characterization, and assay development.
Larry McClain, previously vice president of R&D at Centocor Diagnostics, will manage the new facility, which will also employ two research scientists.
Separately on Wednesday, Ciphergen’s CEO was named a member of Genomica’s board of directors.